Patents Assigned to United Therapeutic Corporation
  • Process to prepare treprostinil, the active ingredient in Remodulin®
    Patent number: 9604901
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 28, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • SALTS OF TREPROSTINIL
    Publication number: 20170073295
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Applicant: UNITED THERAPEUTICS CORPORATION
    Inventors: HITESH BATRA, VIJAY SHARMA, SANMIN YANG, YI ZHANG
  • Synthesis of intermediates for producing prostacyclin derivatives
    Patent number: 9593061
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 14, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Process to prepare treprostinil, the active ingredient in remodulin®
    Patent number: 9593066
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 14, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • PROCESS FOR MAKING BERAPROST
    Publication number: 20170044126
    Abstract: A method is described for making single isomers of synthetic beraprost diol, a key intermediate for making 314-d isomer of beraprost. The method requires fewer steps than the known methods for making these compounds and can be used to scale up the reaction more easily to produce commercial quantities.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 16, 2017
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Liang Guo
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20160355455
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 8, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola
  • METHOD FOR PURIFYING ANTIBODIES
    Publication number: 20160289268
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Application
    Filed: January 14, 2016
    Publication date: October 6, 2016
    Applicants: United Therapeutics Corporation, The U.S.A. as represented by the Secretary, Department of Health and Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Compounds and methods for delivery of prostacyclin analogs
    Patent number: 9422223
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 23, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs
  • Method of identifying therapies for pulmonary hypertension
    Patent number: 9387214
    Abstract: The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 12, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Randy Stephen Sprague, Alan Howard Stephenson, Mary Litchfield Ellsworth, Elizabeth A. Bowles
  • Treprostinil administration by inhalation
    Patent number: 9358240
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 7, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • TREPROSTINIL ADMINISTRATION BY INHALATION
    Publication number: 20160143868
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: February 1, 2016
    Publication date: May 26, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Treprostinil administration by inhalation
    Patent number: 9339507
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 17, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
    Patent number: 9327031
    Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 3, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Roger Andrew Jeffs, David Zaccardelli
  • SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES
    Publication number: 20160107973
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION
    Publication number: 20160068461
    Abstract: The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.
    Type: Application
    Filed: April 17, 2015
    Publication date: March 10, 2016
    Applicant: United Therapeutics Corporation
    Inventor: Vijay Sharma
  • Compounds and methods for delivery of prostacyclin analogs
    Patent number: 9278901
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 8, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20160051505
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 25, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, David MOTTOLA, Roger JEFFS
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20160030371
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Application
    Filed: October 13, 2015
    Publication date: February 4, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs
  • PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
    Publication number: 20150376106
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Sudersan M. TULADHAR, Raju PENMASTA, David A. WALSH
  • Compounds and methods for delivery of prostacyclin analogs
    Patent number: 9199908
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: December 1, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs, Michael Wade